

PHARMACY POLICY STATEMENT

Indiana Medicaid

DRUG NAME	Cabenuva (cabotegravir/rilpivirine)
BILLING CODE	J0741
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Office
STATUS	Prior Authorization Required

Cabenuva is a co-packaged product consisting of 2 different injectable drugs: cabotegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both are once-monthly intramuscular injections given separately at the same time. Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed. Prior to initiating treatment with Cabenuva, oral lead-in dosing (available at no-charge) should be used for approximately 1 month to assess tolerability (Table 3.4 (onset to a



CareSource considers Cabenuva (cabotegravir/rilpivirine) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off- Label policy.

DATE	
------	--